Authorized purpose: Cydar EV provides image guidance by overlaying preoperative 3D vessel anatomy from a previously acquired contrast-enhanced diagnostic CT scan onto live fluoroscopic images to assist positioning guidewires, catheters, and other endovascular devices. It is intended for fluoroscopy-guided endovascular procedures in the lower thorax, abdomen, and pelvis, including AAA and mid-distal TAA repair, angioplasty, stenting, and embolization in specified iliac arteries and corresponding veins, and is not intended for liver, kidney, or pelvic-organ procedures.
Clinical role
Overlay of preoperative 3D vessel anatomy onto live fluoroscopy to assist endovascular device positioning.
Images and patients
Fluoroscopy/Angiography · Lower thorax, abdomen, and pelvis; iliac vessels and corresponding veins
Key limitation
Keep in mind: Use is limited to the labeled lower-thorax, abdomen, pelvis, and vascular procedures; the FDA material excludes X-ray-guided procedures in the liver, kidneys, and pelvic organs.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Cydar EV provides image guidance by overlaying preoperative 3D vessel anatomy from a previously acquired contrast-enhanced diagnostic CT scan onto live fluoroscopic images to assist positioning guidewires, catheters, and other endovascular devices. It is intended for fluoroscopy-guided endovascular procedures in the lower thorax, abdomen, and pelvis, including AAA and mid-distal TAA repair, angioplasty, stenting, and embolization in specified iliac arteries and corresponding veins, and is not intended for liver, kidney, or pelvic-organ procedures.
Which images or clinical context are in scope?Modality: Fluoroscopy/Angiography Anatomy or clinical context: Lower thorax, abdomen, and pelvis; iliac vessels and corresponding veins Input: Previously acquired contrast-enhanced diagnostic CT scans and live fluoroscopic images.
Who uses it?Intended users: Trained physicians and qualified endovascular procedure staff.
What does the software produce?Output: Registered vascular overlays, stored roadmaps, snapshots, and image guidance for guidewire, catheter, and device positioning.
What is its most important limitation?Key limitation: Use is limited to the labeled lower-thorax, abdomen, pelvis, and vascular procedures; the FDA material excludes X-ray-guided procedures in the liver, kidneys, and pelvic organs.
Clinical takeaway. Clinical role: Cydar EV provides image guidance by overlaying preoperative 3D vessel anatomy from a previously acquired contrast-enhanced diagnostic CT scan onto live fluoroscopic images to assist positioning guidewires, catheters, and other endovascular devices. It is intended for fluoroscopy-guided endovascular procedures in the lower thorax, abdomen, and pelvis, including AAA and mid-distal TAA repair, angioplasty, stenting, and embolization in specified iliac arteries and corresponding veins, and is not intended for liver, kidney, or pelvic-organ procedures.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports software verification testing (including registration accuracy calculated from images of the vertebral anatomy) and software validation testing including usability testing with representative clinical users, plus a multi-centre observational clinical study whose primary endpoints were accuracy, robustness, usability, procedure time, radiation exposure, and iodinated contrast volume; it states the clinical endpoint and user feedback data supported the hypothesis of clinical effectiveness. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Cydar EV provides image guidance by overlaying preoperative 3D vessel anatomy from a previously acquired contrast-enhanced diagnostic CT scan onto live fluoroscopic images to assist positioning guidewires, catheters, and other endovascular devices. It is intended for fluoroscopy-guided endovascular procedures in the lower thorax, abdomen, and pelvis, including AAA and mid-distal TAA repair, angioplasty, stenting, and embolization in specified iliac arteries and corresponding veins, and is not intended for liver, kidney, or pelvic-organ procedures.
Use is limited to the labeled lower-thorax, abdomen, pelvis, and vascular procedures; the FDA material excludes X-ray-guided procedures in the liver, kidneys, and pelvic organs.
The exact FDA document reports software verification testing (including registration accuracy calculated from images of the vertebral anatomy) and software validation testing including usability testing with representative clinical users, plus a multi-centre observational clinical study whose primary endpoints were accuracy, robustness, usability, procedure time, radiation exposure, and iodinated contrast volume; it states the clinical endpoint and user feedback data supported the hypothesis of clinical effectiveness. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Software verification testing has been performed in accordance with the software verification plan to cover the system requirements at system/integration and unit levels" … "registration accuracy calculated from images of the vertebral anatomy as documented in". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports software verification testing (including registration accuracy calculated from images of the vertebral anatomy) and software validation testing including usability testing with representative clinical users, plus a multi-centre observational clinical study whose primary endpoints were accuracy, robustness, usability, procedure time, radiation exposure, and iodinated contrast volume; it states the clinical endpoint and user feedback data supported the hypothesis of clinical effectiveness. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Software verification testing has been performed in accordance with the software verification plan to cover the system requirements at system/integration and unit levels" … "registration accuracy calculated from images of the vertebral anatomy as documented in". Read from the exact FDA decision document on 2026-11-14.
Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-04
Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K160088 FDA evidence package for Cydar EV
DesignFDA 510(k) non-clinical performance and clinical investigation support for image guidance and registration.
PopulationLower thorax, abdomen, and pelvis; iliac vessels and corresponding veins
Scopeexact submission
Tested versionCydar EV configuration described in K160088
IndependenceSponsor or vendor study
K160088
The public summary describes standards and clinical investigation support but does not establish a general clinical-outcome benefit or a current service-level commitment.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K160088 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
No separate named-product payment identified in reviewed public material
Centers for Medicare & Medicaid Services · United States
This is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Previously acquired contrast-enhanced diagnostic CT scans and live fluoroscopic images.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA package describes contrast-enhanced CT input, live fluoroscopy, 2D-3D registration using vertebral anatomy, stored roadmaps and snapshots, and application of DICOM standards.
Scope: Exact FDA submission. This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The FDA package describes a software-only solution with cloud communication, storage, and processing accessed over private networks or the public Internet and recommended hardware; current provider, hosting, contract, availability, and security details remain unverified.
Scope: Exact FDA submission. This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Registered vascular overlays, stored roadmaps, snapshots, and image guidance for guidewire, catheter, and device positioning.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Registered vascular overlays, stored roadmaps, snapshots, and image guidance for guidewire, catheter, and device positioning.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The FDA package describes a software-only solution with cloud communication, storage, and processing accessed over private networks or the public Internet and recommended hardware; current provider, hosting, contract, availability, and security details remain unverified.
Exact FDA submission
Checked 2026-09-04
This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.
The FDA package describes contrast-enhanced CT input, live fluoroscopy, 2D-3D registration using vertebral anatomy, stored roadmaps and snapshots, and application of DICOM standards.
Exact FDA submission
Checked 2026-09-04
This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
Only trained physicians and qualified endovascular procedure staff should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor K160088 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Use is limited to the labeled lower-thorax, abdomen, pelvis, and vascular procedures; the FDA material excludes X-ray-guided procedures in the liver, kidneys, and pelvic organs.
Exact FDA submission
Checked 2026-09-04
This is buyer-facing monitoring guidance derived from the exact cleared or authorized scope; it is not a claim that the FDA package provides a live monitoring service.
The FDA package describes a software-only solution with cloud communication, storage, and processing accessed over private networks or the public Internet and recommended hardware; current provider, hosting, contract, availability, and security details remain unverified.
exact submission · checked 2026-09-04
FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.
The FDA package describes contrast-enhanced CT input, live fluoroscopy, 2D-3D registration using vertebral anatomy, stored roadmaps and snapshots, and application of DICOM standards.
exact submission · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Use is limited to the labeled lower-thorax, abdomen, pelvis, and vascular procedures; the FDA material excludes X-ray-guided procedures in the liver, kidneys, and pelvic organs.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.
Monitor K160088 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Use is limited to the labeled lower-thorax, abdomen, pelvis, and vascular procedures; the FDA material excludes X-ray-guided procedures in the liver, kidneys, and pelvic organs.
exact submission · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. fluoroscopy-guided vascular image-navigation software limits remain submission-specific.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
26Fields reviewed
11Source classes checked
3Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads
Three PubMed records and one trial record were screened. They concern Cydar EV, Cydar EV Intelligent Maps, or an AI image-fusion workflow, but none identifies the tested software as the exact K160088 configuration; all four records are quarantined. The current discovery snapshot contains 3 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, fda pma record, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared or authorized configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not publicly available - checked 2026-09-04 - Exact FDA submission
Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
Authorized purpose: OrthoGrid Hip AI 4.0 analyzes two-dimensional C-arm fluoroscopic images to assist positioning of hip-replacement components during direct-anterior total hip arthroplasty.
Authorized purpose: Canon Intelligent NR is a noise-reduction function for fluoroscopic images acquired on compatible Canon radiography and fluoroscopy systems.
Authorized purpose: Trinias is an interventional fluoroscopic X-ray system for diagnostic and interventional angiography, including cardiac, neurovascular, abdominal, peripheral, rotational, multipurpose, and whole-body radiographic or fluoroscopic procedures.
Modality
Fluoroscopy/Angiography
Anatomy
Heart, neurovascular, abdominal, peripheral vessels, and whole body
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.